REPL实时信号 | 通过Getagraph.com最大化利润

购买 107329 min ago

@ $6.89

发出时间: 15 Feb 2024 @ 03:38

回报率: -6.82%

上一信号: Feb 15 - 02:38

上一信号: 出售

回报率: -2.96 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Stats
今日成交量	576 569
平均成交量	1.25M
市值	394.11M
EPS	$0 ( 2024-02-08 )
下一个收益日期	( $-0.860 ) 2024-05-16
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.03
ATR14	$0.00900 (0.14%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Peeples-dyer Veleka	Buy	32 000	Stock Option (right to buy)
2024-04-01	Patel Sushil	Buy	250 000	Employee Stock Option (right to buy)
2024-04-01	Patel Sushil	Buy	83 335	Common Stock
2024-04-01	Pucci Paolo	Buy	32 000	Stock Option (right to buy)
2024-04-01	Xynos Konstantinos	Buy	26 665	Common Stock

INSIDER POWER
74.49
Last 98 transactions
Buy: 2 588 053 \| Sell: 457 936

音量相关性

長: -0.10 (neutral)

短: -0.59 (weak negative)

Signal:(51.385) Neutral

Replimune Group Inc 相关性

10 最正相关
BNIXU	0.927
CASS	0.908
ATIF	0.895
COLL	0.894
COFS	0.893
CNXC	0.893
NIU	0.888
FCBP	0.887
DRTT	0.884
BTAI	0.882

10 最负相关
MTEK	-0.873
NGMS	-0.849
CRSA	-0.842
PPBT	-0.839
PLMR	-0.83
SLDP	-0.828
OSMT	-0.828
MVBF	-0.821
TCRX	-0.821
PMD	-0.819

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Replimune Group Inc 相关性 - 货币/商品

0.70
( moderate )

0.67
( moderate )

0.00
( neutral )

0.34
( neutral )

0.12
( neutral )

-0.23
( neutral )

Replimune Group Inc 财务报表

Annual	2023
营收:	$0
毛利润:	$-2.45M (0.00 %)
EPS:	$-2.99

FY	2023
营收:	$0
毛利润:	$-2.45M (0.00 %)
EPS:	$-2.99

FY	2022
营收:	$0
毛利润:	$-4.58M (0.00 %)
EPS:	$-2.26

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-1.750

Financial Reports:

No articles found.

Replimune Group Inc

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.